Medicare Enrolled

Dr. Raymond De La Rosa, M.D.

Endocrinology · Sarasota, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
8383 S TAMIAMI TRL UNIT 115, Sarasota, FL 34238
9418414206
In practice since 2006 (19 years)
NPI: 1083667984 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. De La Rosa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. De La Rosa? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. De La Rosa

Dr. Raymond De La Rosa is an endocrinology in Sarasota, FL, with 19 years in practice. Based on federal Medicare data, Dr. De La Rosa performed 3,411 Medicare services across 1,404 unique beneficiaries.

Between the years covered by Open Payments, Dr. De La Rosa received a total of $60,295 from 40 pharmaceutical and/or device companies across 369 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in endocrinology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. De La Rosa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 19% volume in FL$ $60,295 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,411
Medicare services
Top 19% in FL for endocrinology
1,404
Unique beneficiaries
$30
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~180 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Denosumab injection (Prolia/Xgeva)1,080$19$46
Office visit, established patient (30-39 min)542$90$264
Blood draw (venipuncture)468$8$17
Comprehensive metabolic blood panel302$10$21
Thyroid stimulating hormone (TSH) test241$16$34
Hemoglobin A1c test (diabetes monitoring)209$9$19
Free thyroxine (T4) test116$9$18
Vitamin D level test74$29$59
Lipid panel (cholesterol and triglycerides)71$13$27
New patient office visit (45-59 min)71$113$347
Urine microalbumin test (kidney screening)60$6$12
Creatinine test (kidney function)60$5$10
Office visit, established patient, complex (40-54 min)43$127$370
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report23$27$71
Drug injection, under skin or into muscle22$11$31
Cortisol (hormone) measurement, total17$16$33
New patient office visit, complex (60-74 min)12$144$458
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$60,295
Total received (2018-2024)
Avg $8,614/year across 7 years
Top 9% in FL for endocrinology
40
Companies
369
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$53,015 (87.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,373 (8.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,908 (3.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,260
2023
$2,143
2022
$675
2021
$649
2020
$958
2019
$14,404
2018
$40,206

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novo Nordisk Inc
$44,213
Boehringer Ingelheim Pharmaceuticals, Inc.
$5,594
SANOFI-AVENTIS U.S. LLC
$4,766
Lilly USA, LLC
$1,080
Abbott Laboratories
$809
AstraZeneca Pharmaceuticals LP
$656
Amgen Inc.
$648
Radius Health, Inc.
$365
Esperion Therapeutics, Inc.
$254
Bayer Healthcare Pharmaceuticals Inc.
$205
Merck Sharp & Dohme Corporation
$188
Bayer HealthCare Pharmaceuticals Inc.
$184
Dexcom, Inc.
$161
Janssen Pharmaceuticals, Inc
$118
Kowa Pharmaceuticals America, Inc.
$109
Novartis Pharmaceuticals Corporation
$94
AbbVie Inc.
$80
Corcept Therapeutics
$79
Amarin Pharma Inc.
$74
ABBVIE INC.
$65
Tandem Diabetes Care, Inc.
$63
Kyowa Kirin, Inc.
$63
Boston Scientific Corporation
$55
Insulet Corporation
$51
Genentech USA, Inc.
$43
Xeris Pharmaceuticals, Inc.
$31
Takeda Pharmaceuticals U.S.A., Inc.
$28
UCB, Inc.
$25
Aurinia Pharma U.S., Inc.
$22
Exact Sciences Corporation
$22
PFIZER INC.
$20
Strongbridge US INC.
$17
Eisai Inc.
$16
Orexigen Therapeutics, Inc.
$15
Biohaven Pharmaceutical Holding Company Ltd.
$15
IBSA Pharma Inc.
$15
Mannkind Corporation
$15
Shire North American Group Inc
$12
Scilex Pharmaceuticals Inc.
$12
Teva Pharmaceuticals USA, Inc.
$11
Top 3 companies account for 90.5% of total payments
Associated products mentioned in payments ›
AFREZZA · AIRSUPRA · AJOVY · Aimovig · BREZTRI · BYDUREON · Bimzelx · CONTRAVE · CREON · Cologuard Collection Kit · DEXCOM G7 GSS (161) · Dayvigo · Dexcom G6 Transmitter · EMGALITY · ENTRESTO · EVENITY · FARXIGA · FIASP · FREESTYLE LIBRE 2 · FREESTYLE LIBRE 3 · FreeStyle Libre · FreeStyle Libre 2 · FreeStyle Libre blood glucose Flash Monitoring System · FreeStyle Lite system · GVOKE PFS · HUMULIN · INVOKANA · JANUVIA · JARDIANCE · Kerendia · Korlym · LEQVIO · LUPKYNIS · Licart · Livalo · MACRILEN · MOUNJARO · NATPARA · NEXLETOL · NEXLIZET · NURTEC ODT · Omnipod · Otezla · Ozempic · PAXLOVID · QULIPTA · Repatha · Rybelsus · SOLIQUA · SYNTHROID · Saxenda · TALTZ · TEPEZZA · TOUJEO · TRINTELLIX · TRULICITY · TZIELD · Tresiba · Tymlos · UBRELVY · VRAYLAR · Vascepa · Victoza · WATCHMAN Access System · Wegovy · XARELTO · Xofluza · Xultophy 100/3.6 · ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH · t:slim X2 Insulin Pump with Control-IQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (88%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in endocrinology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 9% for endocrinology in FL.

Equivalent to $1,768 per 100 Medicare services performed
Looking for a endocrinology in Sarasota?
Compare endocrinologys in the Sarasota area by procedure volume, costs, and industry payment transparency.
Browse endocrinologys nearby

Geographic Context

Endocrinologys within 10 mi
24
Per 100K population
5.3
County median income
$80,633
Nearest hospital
HCA FLORIDA SARASOTA DOCTORS HOSPITAL
3.1 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. De La Rosa is a clinical cardiology specialist, with above-average Medicare volume (top 19% in FL), and high industry engagement (speaking/promotional, top 9%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. De La Rosa experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. De La Rosa performed 1,080 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. De La Rosa receive payments from pharmaceutical companies?
Yes. Dr. De La Rosa received a total of $60,295 from 40 companies across 369 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. De La Rosa's costs compare to other endocrinologys in Sarasota?
Dr. De La Rosa's average Medicare payment per service is $30. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. De La Rosa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →